Just in, from our friend, Dr. Scott Perry

This amazing news just in from our friend Dr. Scott Perry :

It has been an exciting journey as PI of Swallowtail, the open label extension study for STK-001, working alongside Stoke Therapeutics to develop disease-modifying therapy for Dravet! Looking forward to continuing this important work and seeing how it impacts the future of people with DravetSyndrome! 💜

Children with a rare and difficult-to-control form of epilepsy called Dravet syndrome have new hope thanks to landmark research data showing the effectiveness of an RNA-based medicine, STK-001, to improve seizure control and modify disease progression.

The complete article can be found at: